Business
The limited supply of this common reagent is set to drive drug prices higher, but there are ways for companies to lessen the impact.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Bluebird bio reported first-quarter earnings, the approval of Abecma, the first CAR-T therapy for relapsed or refractory multiple myeloma, and its spinout, 2seventy bio, and its leadership.
BioSpace recently spoke with Jonathan Rigby, Group CEO of Revolo Biotherapeutics, a biotherapeutic company working to revolutionize the treatment of autoimmune and allergic disease by achieving superior long-term disease remission through resetting the immune system.
Theranos founder Elizabeth Holmes is back in the courtroom for the first time in 15 months for a three-day hearing ahead of her criminal fraud trial.
Here’s a look at Pfizer-BioNTech, Novavax and the COVID-19 vaccine’s sales, approval in children, additional trials, potential of booster shots, and more.
Roger Perlmutter, the former president of Merck Research Laboratories, will helm drug discovery startup Eikon Therapeutics, Inc.
There’s money on the move and venture capital firms launch several biotech companies with hefty Series A financing rounds. Here’s a look.
April showers bring May dollars. Here’s whose cash gardens are really blooming this week in the life sciences world.
Companies across the biotech and biopharma industries recently reported a slew of new leadership appointments, several of which have been explicitly focused on the fields of oncology and precision medicine.
Pfizer reported its first-quarter 2021 revenues of $14.6 billion, an impressive 42% operational growth.
Neuroelectrics, based in Barcelona, Spain with offices in Cambridge, Massachusetts, announced it had raised $17.5 million in a Series A financing round. It was led by Morningside Ventures.